Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1186/s13046-020-01590-2 http://scihub22266oqcxt.onion/10.1186/s13046-020-01590-2 32398164!7214852!32398164     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Exp+Clin+Cancer+Res 2020 ; 39 (1): 86 Nephropedia Template TP {{tp|p=32398164|t=2020. Drug repurposing against COVID-19: focus on anticancer agents |pdf=|usr=}}{{32398164}} gab.com Text Drug repurposing against COVID-19: focus on anticancer agents JO: J Exp Clin Cancer Res http://www.kidney.de/pget.php?&tw=1&pmid=32398164 #FOAvip BACKGROUND: The very limited time allowed to face the COVID-19 pandemic poses a pressing challenge to find proper therapeutic approaches. However, synthesis and full investigation from preclinical studies to phase III trials of new medications is a time-consuming procedure, and not viable in a global emergency, such as the one we are facing. MAIN BODY: Drug repurposing/repositioning, a strategy effectively employed in cancer treatment, can represent a valid alternative. Most drugs considered for repurposing/repositioning in the therapy of the COVID-19 outbreak are commercially available and their dosage and toxicity in humans is well known, due to years (or even decades) of clinical use. This can allow their fast-track evaluation in phase II-III clinical trials, or even within straightforward compassionate use. Several drugs being re-considered for COVID-19 therapy are or have been used in cancer therapy. Indeed, virus-infected cells are pushed to enhance the synthesis of nucleic acids, protein and lipid synthesis and boost their energy metabolism, in order to comply to the "viral program". Indeed, the same features are seen in cancer cells, making it likely that drugs interfering with specific cancer cell pathways may be effective as well in defeating viral replication. SHORT CONCLUSION: To our knowledge, cancer drugs potentially suitable for facing SARS-CoV-2 infection have not been carefully reviewed. We present here a comprehensive analysis of available information on potential candidate cancer drugs that can be repurposed for the treatment of COIVD-19. Twit Text FOAVip Drug repurposing against COVID-19: focus on anticancer agents ????J Exp Clin Cancer Res http://www.kidney.de/pget.php?&tw=1&pmid=32398164 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32398164 #FOAvip English Wikipedia <ref>{{Cite pmid|32398164}}</ref> Drug repurposing against COVID-19: focus on anticancer agents #MMPMID32398164 Ciliberto G; Mancini R; Paggi MG J Exp Clin Cancer Res 2020[May]; 39 (1): 86 PMID32398164show ga BACKGROUND: The very limited time allowed to face the COVID-19 pandemic poses a pressing challenge to find proper therapeutic approaches. However, synthesis and full investigation from preclinical studies to phase III trials of new medications is a time-consuming procedure, and not viable in a global emergency, such as the one we are facing. MAIN BODY: Drug repurposing/repositioning, a strategy effectively employed in cancer treatment, can represent a valid alternative. Most drugs considered for repurposing/repositioning in the therapy of the COVID-19 outbreak are commercially available and their dosage and toxicity in humans is well known, due to years (or even decades) of clinical use. This can allow their fast-track evaluation in phase II-III clinical trials, or even within straightforward compassionate use. Several drugs being re-considered for COVID-19 therapy are or have been used in cancer therapy. Indeed, virus-infected cells are pushed to enhance the synthesis of nucleic acids, protein and lipid synthesis and boost their energy metabolism, in order to comply to the "viral program". Indeed, the same features are seen in cancer cells, making it likely that drugs interfering with specific cancer cell pathways may be effective as well in defeating viral replication. SHORT CONCLUSION: To our knowledge, cancer drugs potentially suitable for facing SARS-CoV-2 infection have not been carefully reviewed. We present here a comprehensive analysis of available information on potential candidate cancer drugs that can be repurposed for the treatment of COIVD-19. |*Drug Repositioning[MESH] |Antineoplastic Agents/*pharmacology[MESH] |Antiviral Agents[MESH] |Betacoronavirus[MESH] |COVID-19[MESH] |Coronavirus Infections/*drug therapy[MESH] |Humans[MESH] |Immunomodulation[MESH] |Pandemics[MESH] |Pneumonia, Viral/*drug therapy[MESH] |SARS-CoV-2[MESH]Drug repurposing against COVID-19: focus on anticancer agents (epmc).pdf DeepDyve Pubget Overpricing